What are you looking for?
This episode of The Ophthalmic Project explores the 100-year legacy of ZEISS in the United States, tracing its origins from a small optics workshop in 1846 to a global leader...
In a new episode of The Ophthalmic Project, Mark Dlugoss speaks with Joshua Moriarty, CEO of Okogen, to discuss a new product in development for infectious conjunctivitis. Mark Dlugoss: Healthcare...
In a new episode of The Ophthalmic Project, Mark Dlugoss speaks with Jim Mazzo, president of the Ophthalmology Foundation and executive chairman at Neurotech Pharmaceuticals, about what the Foundation is...
In the latest episode of The Ophthalmic Project, Mark Dlugoss speaks with Sean Ianchulev, MD, MPH, of Iantrek Inc., about the company’s latest advancements in glaucoma care. Mark Dlugoss: Innovation... ...
In the latest episode of The Ophthalmic Project, Mark Dlugoss speaks with Tom Mitro, President and CEO of Signal 12, to discuss an innovative approach the company is pursuing for...
In this episode of The Ophthalmic Project, Mark Dlugoss, Senior Contributing Editor for Ophthalmology 360, interviews John W. Sheets, PhD, about Pantheon Vision’s bioengineering solutions for corneal transplants. Mark Dlugoss:...
Mark Dlugoss: Artificial intelligence is one of the hottest topics in ophthalmology and vision care today. Its potential is expected to revolutionize how eye care clinicians diagnose and treat their...
Mark Dlugoss: In April 2000 the FDA approved photodynamic therapy using VISUDYNE for the treatment of neovascular age-related macular degeneration. It was the first pharmacological treatment for retina disease. Since...
Mark Dlugoss: The American Academy of Ophthalmology’s annual meeting is the leading ophthalmic conference that attracts ophthalmologists from around the world. The four-day event features papers, keynote lecturers, instructional courses,... ...